Loading…
Coherus Oncology, Inc. is projected to rise to $1.78 by 2027, a +16% move from its current price of $1.54. CHRS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $1.49 | $1.54 | $1.59 | +0.04% |
| Jul 15 | $1.47 | $1.54 | $1.62 | +0.07% |
| Jul 16 | $1.46 | $1.54 | $1.63 | +0.11% |
| Jul 17 | $1.44 | $1.54 | $1.65 | +0.15% |
| Jul 18 | $1.43 | $1.54 | $1.66 | +0.19% |
| Jul 19 | $1.42 | $1.54 | $1.67 | +0.22% |
| Jul 20 | $1.41 | $1.54 | $1.69 | +0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.41 | $1.54 | $1.69 | +0.26% |
| Week 2 | $1.37 | $1.55 | $1.75 | +0.52% |
| Week 3 | $1.33 | $1.55 | $1.81 | +0.79% |
| Week 4 | $1.31 | $1.56 | $1.86 | +1.05% |
| Week 5 | $1.28 | $1.56 | $1.90 | +1.32% |
| Week 6 | $1.26 | $1.56 | $1.94 | +1.58% |
| Week 7 | $1.24 | $1.57 | $1.98 | +1.85% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Coherus Oncology, Inc. is a biopharmaceutical company that researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc.
and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients.
The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Coherus Oncology, Inc. (CHRS) is a small-cap healthcare stock with a current price of $1.54 and a market capitalization of $237.54M. It ranks 3671 by size among listed equities. The near-term price picture shows a balanced view with a neutral technical posture, supported by present moving averages and established price levels.
The stock operates in the Healthcare category and sits within a modest capitalization band.
A major floor 21.2% below — a decisive break under it would weaken the trend.
The nearest floor, 11.7% below — buyers have tended to step in here.
The nearest ceiling, 8.4% above — a clean break opens room to run.
A major ceiling 29.2% above — clearing it would confirm fresh momentum.
Key CHRS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CHRS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.61 | Sell | $1.58 | Sell |
| MA 10 | $1.53 | Buy | $1.55 | Sell |
| MA 20 | $1.48 | Buy | $1.52 | Buy |
| MA 50 | $1.57 | Sell | $1.56 | Sell |
| MA 100 | $1.64 | Sell | $1.59 | Sell |
| MA 200 | $1.62 | Sell | $1.55 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.08 | Neutral |
| Stoch RSI (14) | 45.71 | Neutral |
| CCI (20) | 55.15 | Neutral |
| Williams %R (14) | -48.15 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 5.48 | Buy |
| Bollinger %B (20,2) | 0.66 | Neutral |
| Stochastic %K (14) | 51.85 | Neutral |
| TRIX (15) | -0.12 | Sell |
| Awesome (5,34) | 0.11 | Buy |
| Ultimate (7,14,28) | 61.07 | Neutral |
| Momentum (10) | 0.06 | Buy |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 1.67 | Sell |
| ADX (14) | 13.39 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is neutral. The RSI14 sits at 50, with the 50-day moving average at $1.57 and the 200-day moving average at $1.62, placing the price near the middle of its longer-term trend. Immediate support sits at $1.36 and resistance at $1.67, framing a current trading band.
Over the past 30 days, the price has fluctuated within a range of $1.24 to $1.92.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.36 | $1.54 | $2.15 | 0% | Neutral | |
| $1.39 | $1.78 | $2.43 | +16% | Neutral | |
| $1.38 | $1.83 | $2.61 | +19% | Neutral | |
| $1.40 | $1.91 | $2.82 | +24% | Bullish | |
| $1.63 | $2.28 | $3.47 | +48% | Bullish | |
| $1.85 | $2.65 | $4.12 | +72% | Bullish | |
| $2.10 | $3.08 | $4.89 | +100% | Bullish | |
| $2.35 | $3.52 | $5.72 | +129% | Bullish | |
| $2.27 | $3.47 | $5.74 | +125% | Bullish | |
| $2.34 | $3.64 | $6.12 | +136% | Bullish | |
| $3.28 | $5.58 | $10.07 | +262% | Bullish | |
| $5.07 | $10.08 | $20.15 | +554% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.36 | $1.54 | $1.81 | +0.00% |
| August 2026 | $1.29 | $1.53 | $1.88 | -0.43% |
| September 2026 | $1.33 | $1.59 | $1.98 | +3.91% |
| October 2026 | $1.32 | $1.59 | $1.99 | -0.32% |
| November 2026 | $1.32 | $1.60 | $2.02 | +0.61% |
| December 2026 | $1.38 | $1.68 | $2.15 | +5.22% |
Click any year to see its month-by-month CHRS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CHRS could reach as high as $2.15, with a base case around $1.54 and support toward $1.36 — roughly 0% from $1.54. A consolidation phase looks the most probable path here.
Expect CHRS to range from $1.39 to $2.43 through 2027. The $1.78 average target implies a +16% move from current prices. That is up +16% on the projected 2026 average. Price action looks broadly range-bound.
The CHRS price prediction for 2028 points to an average of $1.83 (low $1.38, high $2.61) — a potential gain of +19% on today's $1.54. A consolidation phase looks the most probable path here.
In 2029, CHRS is projected to trade between $1.40 and $2.82, averaging $1.91 — a potential gain of +24% from today's $1.54. That is up +5% on the projected 2028 average. Momentum favours further upside here.
Coherus Oncology, Inc.'s 2030 outlook centres on $2.28, within a $1.63 to $3.47 range. That is up +19% on the projected 2029 average. That marks a +48% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, CHRS could reach as high as $4.12, with a base case around $2.65 and support toward $1.85 — roughly +72% from $1.54. Momentum favours further upside here.
Expect CHRS to range from $2.10 to $4.89 through 2032. The $3.08 average target implies a +100% move from current prices. That is up +16% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The CHRS price prediction for 2033 points to an average of $3.52 (low $2.35, high $5.72) — a potential gain of +129% on today's $1.54. Momentum favours further upside here.
In 2034, CHRS is projected to trade between $2.27 and $5.74, averaging $3.47 — a potential gain of +125% from today's $1.54. That is -1% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
Coherus Oncology, Inc.'s 2035 outlook centres on $3.64, within a $2.34 to $6.12 range. That is up +5% on the projected 2034 average. That marks a +136% change versus current levels. Momentum favours further upside here.
By 2040, CHRS could reach as high as $10.07, with a base case around $5.58 and support toward $3.28 — roughly +262% from $1.54. Buyers look set to stay in control over this stretch.
Expect CHRS to range from $5.07 to $20.15 through 2050. The $10.08 average target implies a +554% move from current prices. That is up +81% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CHRS today (≈ 649.350649 CHRS) could be worth
$6,544.94
+$5,544.94 (+554%) by 2050 · US Dollar
Based on the average projected CHRS price of $10.08 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CHRSwould be worth at today's price.
$1,000 invested in CHRS on Jul 10, 2025 (≈ 1,153.402559 CHRS) would be worth
$1,776.24
+$776.24 (+77.6%) today · 1.78× · US Dollar
Based on a CHRS entry price of $0.867 vs. today's $1.54.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.45 | $1,062.07 | +6.2% |
| 1 month ago | $1.36 | $1,132.35 | +13.2% |
| 3 months ago | $1.68 | $916.67 | -8.3% |
| 6 months ago | $1.65 | $933.33 | -6.7% |
| 1 year ago | $0.867 | $1,776.24 | +77.6% |
| All time (5.0y) ago | $13.14 | $117.2 | -88.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CHRS forecast.
Our base-case forecast reaches $3.10 around 2033.
Implied market cap at $3.10: $478.17M
Forecasts project a rising path for CHRS over the coming years. In 2026, the average price is $1.54 with a range from $1.36 to $2.15 and a forecasted ROI of 0 with a neutral sentiment. The outlook strengthens into 2027–2028, with average prices of $1.78 and $1.83 and ROI of 15.5 and 18.7, respectively.
In 2029, the average price is $1.91 with a bullish sentiment and a forecasted ROI of 24.3. By 2030, the average price rises to $2.28 with a 48.1 ROI; 2031 shows $2.65 average and 72.1 ROI; 2032 shows $3.08 average and 99.9 ROI; 2033 shows $3.52 average and 128.5 ROI; 2034 shows $3.47 average and 125.5 ROI; 2035 shows $3.64 average and 136.4 ROI. The long-run path becomes distinctly bullish, with 2040 showing an average price of $5.58 and a 262.5 ROI, and 2050 an average price of $10.09 with a 555.3 ROI and bullish sentiment.
Tap a question to reveal the answer.
The forecast lists an average price of $2.28, a min of $1.63, a max of $3.46, and a forecasted ROI of 48.1 with bullish sentiment.
Forecasts show the average price rising to $10.09 by 2050 with a ROI of 555.3 and bullish sentiment from 2029 onward.
Yes—the 2050 forecast maximum is $20.17 with a bullish sentiment and ROI of 555.3.
Current price is $1.54 and market capitalization is $237.54M.
The 30-day range is $1.24 to $1.92.
Coherus Oncology, Inc. Community Discussion
0Share your Coherus Oncology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.